Company: SMNR
Filing Date: 2025-08-08
Form Type: S-4/A
Source: 0001193125-25-177097
Chunk: 381

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-08
Form: S-4/A
Chunk 381
---
osals.

Pursuant to the Letter Agreement and the Sponsor Support Agreement, the Initial Shareholders holding an aggregate of 1,562,500 Denali Class B Ordinary Shares (or 59.7% of the outstanding Denali Class B Ordinary Shares have agreed to attend the Meeting and vote their respective Denali Class B Ordinary Shares) in favor of each of the Proposals. As a result, no Denali Class A Ordinary Shares held by the public shareholders will need to be present in person or by proxy to satisfy the quorum requirement for the Meeting. In addition, as the vote to approve the Business Combination Proposal requires the affirmative vote of the majority of the Denali Ordinary Shares present in person or represented by proxy and entitled to vote thereon and who vote at the Meeting or any adjournment or postponement thereof, then at which a quorum is present, assuming only the minimum number of Denali Ordinary Shares to constitute a quorum is present, none of the outstanding Denali Class A Ordinary Shares held by the public shareholders must be voted in favor of the Business Combination Proposal for it to be approved and, therefore, it could be approved without any votes by any public shareholders. See the section titled “The Merger Agreement–Certain Related Agreements and Arrangements–Sponsor Support Agreement” for more information.

Resolution to be Voted Upon

The full text of the resolution to be passed is as follows:

“RESOLVED, AS AN ORDINARY RESOLUTION THAT, the transactions contemplated under the Agreement and Plan of Merger, dated as of August 30, 2024 (as it may be amended or restated from time to time in accordance with its terms, including by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 16, 2025 (“Amendment No. 1 to Merger Agreement”) and Amendment No. 2 to Agreement and Plan of Merger, dated as of July 22, 2025 (the “Amendment No. 2 to Merger Agreement”), the “Merger Agreement”), by and among Denali, Denali Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Denali (“Merger Sub”), and Semnur Pharmaceuticals, Inc., a Delaware corporation (“Semnur”) and majority owned subsidiary of Scilex Holding Company (“Scilex”), with Semnur surviving the merger (the “Business Combination”), copies of each of which are attached to this proxy statement/prospectus as Annex A